Pharmicell Co., Ltd.
🇰🇷South Korea
Clinical Trials
16
Active:2
Completed:5
Trial Phases
4 Phases
Phase 1:6
Phase 2:3
Phase 3:2
+1 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (12 trials with phase data)• Click on a phase to view related trials
Phase 1
6 (50.0%)Phase 2
3 (25.0%)Phase 3
2 (16.7%)Not Applicable
1 (8.3%)Long-term Follow-up of Patients With Chronic Kidney Disease Who Had Administered Cellgram-CKD in PMC-P-12 Study
Active, not recruiting
- Conditions
- Renal Insufficiency, Chronic
- First Posted Date
- 2021-10-27
- Last Posted Date
- 2024-03-25
- Lead Sponsor
- Pharmicell Co., Ltd.
- Target Recruit Count
- 10
- Registration Number
- NCT05096182
- Locations
- 🇰🇷
Asan Medical Center Hospital, Seoul, Korea, Republic of
Long-term Follow-up of Patients With Alcoholic Liver Cirrhosis Who Had Administered Cellgram-LC in PMC-P-07 Study
Not Applicable
Recruiting
- Conditions
- Alcoholic Cirrhosis
- First Posted Date
- 2021-10-26
- Last Posted Date
- 2024-03-21
- Lead Sponsor
- Pharmicell Co., Ltd.
- Target Recruit Count
- 100
- Registration Number
- NCT05093881
- Locations
- 🇰🇷
Soonchunhyang University Hospital, Seoul, Korea, Republic of
🇰🇷Gangwon National University Hospital, ChunCheon, Korea, Republic of
🇰🇷Hallym Univ. Medical Center, ChunCheon, Korea, Republic of
Clinical Trial to Evaluate Safety of Allogeneic Bone Marrow Derived Mesenchymal Stem Cell in Chronic Kidney Disease
Phase 1
Completed
- Conditions
- Chronic Kidney Disease stage4Chronic Kidney Disease Stage 3B
- First Posted Date
- 2021-09-13
- Last Posted Date
- 2024-03-22
- Lead Sponsor
- Pharmicell Co., Ltd.
- Target Recruit Count
- 10
- Registration Number
- NCT05042206
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
Clinical Trial to Evaluate the Efficacy and Safety of Cellgram-LC Administration in Patients With Alcoholic Cirrhosis
Phase 3
Recruiting
- Conditions
- Alcoholic Cirrhosis
- First Posted Date
- 2020-12-30
- Last Posted Date
- 2024-03-21
- Lead Sponsor
- Pharmicell Co., Ltd.
- Target Recruit Count
- 200
- Registration Number
- NCT04689152
- Locations
- 🇰🇷
Soonchunhyang University Hospital, Seoul, Korea, Republic of
🇰🇷Gangwon National University Hospital, ChunCheon, Korea, Republic of
🇰🇷Hallym Univ. Medical Center, ChunCheon, Korea, Republic of
Safety Evaluation of Autologous Dendritic Cell Anticancer Immune Cell Therapy (Cellgram-DC-PC)
Phase 1
Terminated
- Conditions
- Castration Resistant Prostate Cancer, CRPC
- First Posted Date
- 2020-11-04
- Last Posted Date
- 2023-01-03
- Lead Sponsor
- Pharmicell Co., Ltd.
- Target Recruit Count
- 3
- Registration Number
- NCT04615845
- Locations
- 🇰🇷
Asan medical center, Seoul, Korea, Republic of
- Prev
- 1
- 2
- 3
- 4
- Next
News
No news found